Monte Rosa Q3 net loss $27.3M; MRT-2359 Phase 1/2 dosing initiated

Monte Rosa Therapeutics, Inc.

Net loss of $27.3M in Q3 2022 vs $19.8M in Q3 2021; R&D expenses rose to $21.3M.
Cash, equivalents, and marketable securities $277.4M as of Sep 30, 2022; runway into late 2024.
Initiated patient dosing in Phase 1/2 trial for MRT-2359 (GSPT1 degrader) in MYC-driven solid tumors.
VAV1 molecular glue degrader program advanced into lead optimization for autoimmune diseases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.